PT  - JOURNAL ARTICLE
ED  - ,
TI  - Correction: management of prostatic carcinoma (3 November 1986, p87)
AID  - 10.1136/dtb.26.1.4
DP  - 1988 Jan 11
TA  - Drug and Therapeutics Bulletin
PG  - 4--4
VI  - 26
IP  - 1
4099  - http://dtb.bmj.com/content/26/1/4.short
4100  - http://dtb.bmj.com/content/26/1/4.full
SO  - Drug Ther Bull1988 Jan 11; 26
AB  - We stated that aminoglutethimide, which has been considered as an alternative to adrenalectomy in metastatic carcinoma of the prostate, reduces adrenal production of androgen and cortisol. There is evidence that this is not so, and that aminoglutethimide given alone raises adrenal androgen production.1 In almost all published work on its use in prostatic cancer aminoglutethimide has been given with a glucocorticoid, and it is evidently the glucocorticoid which suppresses adrenal androgen production.2 It is not clear therefore whether the use of aminoglutethimide with hydrocortisone offers any advantage over that of hydrocortisone alone.